Adjuvant bidirectional chemotherapy with intraperitoneal pemetrexed combined with intravenous Cisplatin for diffuse malignant peritoneal mesothelioma. (Record no. 5817)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 02416nam a22003137a 4500 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 201229s20122012 xxu||||| |||| 00| 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
International Standard Serial Number | 1687-6121 |
040 ## - CATALOGING SOURCE | |
Original cataloging agency | Ovid MEDLINE(R) |
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
PMID | 22927839 |
245 ## - TITLE STATEMENT | |
Title | Adjuvant bidirectional chemotherapy with intraperitoneal pemetrexed combined with intravenous Cisplatin for diffuse malignant peritoneal mesothelioma. |
251 ## - Source | |
Source | Gastroenterology research & practice. 2012:890450, 2012. |
252 ## - Abbreviated Source | |
Abbreviated source | Gastroenterol Res Pract. 2012:890450, 2012. |
253 ## - Journal Name | |
Journal name | Gastroenterology research and practice |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Year | 2012 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Manufacturer | FY2012 |
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] | |
Publication status | ppublish |
266 ## - Date added to catalog | |
Date added to catalog | 2020-12-29 |
520 ## - SUMMARY, ETC. | |
Abstract | Cytoreductive surgery (CRS) with heated intraoperative intraperitoneal chemotherapy (HIPEC) has emerged as optimal treatment for diffuse malignant peritoneal mesothelioma (DMPM) showing median survivals of 36-92 months. However, recurrences occur frequently even in patients undergoing optimal cytreduction and are often confined to the abdomen. We initiated a Phase II study of adjuvant intraperitoneal pemetrexed combined with intravenous cisplatin for patients undergoing CRS and HIPEC for DMPM. The treatment consisted of pemetrexed 500 mg/m(2) intraperitoneally and cisplatin 50 mg/m(2) intravenously given simultaneously on day 1 of every 21 day cycle for 6 cycles. The primary endpoint of the study was treatment related toxicity. From July 2007 until July 2009 ten patients were enrolled. Nine of 10 completed all 6 cycles of adjuvant treatment per protocol. The most common toxicities were fatigue, nausea and abdominal pain grade 1 or 2. There was one grade 3 toxicity consisting of a catheter infection. The median survival for all 10 patients was 33.5 months. Pharmacokinetic analysis of intraperitoneal pemetrexed showed a peritoneal to plasma area under the curve ratio of 70. Our study shows that adjuvant intravenous cisplatin and intraperitoneal pemetrexed can be used following CRS and HIPEC for DMPM with low morbidity. |
546 ## - LANGUAGE NOTE | |
Language note | English |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | IN PROCESS -- NOT YET INDEXED |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME | |
Institution | Washington Cancer Institute |
657 ## - INDEX TERM--FUNCTION | |
Medline publication type | Journal Article |
700 ## - ADDED ENTRY--PERSONAL NAME | |
Local Authors | Bijelic, Lana |
700 ## - ADDED ENTRY--PERSONAL NAME | |
Local Authors | Stuart, O Anthony |
700 ## - ADDED ENTRY--PERSONAL NAME | |
Local Authors | Sugarbaker, Paul H |
790 ## - Authors | |
All authors | Bijelic L, Stuart OA, Sugarbaker P |
856 ## - ELECTRONIC LOCATION AND ACCESS | |
DOI | <a href="https://dx.doi.org/10.1155/2012/890450">https://dx.doi.org/10.1155/2012/890450</a> |
Public note | https://dx.doi.org/10.1155/2012/890450 |
942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
Koha item type | Journal Article |
Item type description | Article |
Withdrawn status | Lost status | Damaged status | Not for loan | Collection | Home library | Current library | Date acquired | Total Checkouts | Full call number | Barcode | Date last seen | Price effective from | Koha item type |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MedStar Authors Catalog | MedStar Authors Catalog | 12/29/2020 | 22927839 | 22927839 | 12/29/2020 | 12/29/2020 | Journal Article |